Future Studies Sample Clauses

Future Studies. More studies need to be done in the field to test hands, objects, food sand, soil, and fecal sludge. These studies need to be done in low-resource settings, in the field to simulate the settings where testing capability is most needed. Whether they succeed or fail, results should be written up for development of the testing methods. Furthermore, as mentioned above, more of an effort should be made, through qualitative research, to understand how well monitoring is understood and whether or not it would be adopted. It would also be useful to continue to make efforts towards statistically determining an appropriate number of samples to collect. The methodology of the study from 2005 by Shukla, et. al raised a lot of questions and likely cannot be applied to study designs now. But, oftentimes, the number of samples collected seems to be chosen randomly or a priori. If a more methodical way to arrive at a cost-effective, precise sample taking variability in account, it would be extremely beneficial. Finally, a comparative study with each matrix in the future would be helpful. If all of these methods could be compared in one setting, allowing for the control of all other factors, it would provide the best picture of which method is best for each matrix. If this comparative study could be done, the reliability and robustness of each method could be documented as well. In low-resource settings, these characteristics would be especially important as circumstances are always subject to change. A few articles started to discuss robustness of the Petrifilm and IDEXX in terms of temperature and time, but there is not yet enough data to know if the performance of these methods is as expected in less than perfect temperatures and time. It would also be beneficial to know, for example, how the ability to maintain sterility affects the methods. Matrix-Specific recommendations.
AutoNDA by SimpleDocs
Future Studies. It is possible that you may qualify to participate in future studies related to weight management or heart health. If you would like to be contacted about future studies that you may qualify for, including phone-based follow-ups to hear how you are doing after the program ends, please indicate your choice below. If you would like to grant us permission to contact you, your contact information will be stored in a secure list under the Principal Investigator’s control. Your information will not be distributed to anyone outside of the Weight Control and Diabetes Research Lifespan - Rhode Island Hospital IRB 1 IRBNet ID: 1102103-22 Approved: August 17, 2021 Expiration: August 16, 2022 Does not expire if expiration date is blank Study Volunteer Initials Center or Lifespan’s Cardiac Rehabilitation. You will only be contacted about specific studies that may interest you that we believe you may qualify for. You have my permission to contact me about future studies that I may qualify for. I do not give my permission for you to contact me about future studies that I may qualify for. Signature of study volunteer Date You have the right to change your mind at any time regarding being contacted about future studies or follow-ups. If you decide to quit the study please tell the head researcher, Xx. Xxxxx X. Goldstein, PhD, at 000-000-0000 or xxxxx.xxxxxxxxx@xxxxxxxx.xxx. Costs for participating in this study Some of the services you will receive are being performed only because you are participating in this research study. Examples of these ‘research only’ services include access to the online core weight loss program and access to any of the additional components (e.g., the fitness tracker, the virtual meetings). Those services will be paid for by the study and will not be billed to you or your health insurance company. Other services you will receive during this research study are considered "routine clinical services" that you would have received even if you were not in the research study. Examples are the services involved in your participation in cardiac rehabilitation. These services will be billed to your health insurance company, but you will be responsible for paying any deductibles, co-payments, or co- insurance that are a normal part of your health insurance plan. If you do not have health insurance, you will be responsible for those costs. Contact Information: This study’s primary investigator is Xx. Xxxxx X. Goldstein, PhD, Research Scientist for The Xxxxxx...
Future Studies. Results from this study suggest that parents experiencing stress due to an adolescent’s substance use are generally aware of many aspects of the teen’s substance use, but their degree of correspondence with the teen’s report varies with the substance used and its measurement. Though additional studies are necessary, the findings suggest that in research or treatment settings in which an adolescent is uncooperative or unavailable, parental report of at least the frequency of alcohol and other substance use may serve as a proxy. Adolescents’ Time Use (cont’d) • Adolescents spent an average of nearly six hours a week playing sports. • After combining six categories of family time (e.g., eating dinner with family, doing things with parents, family celebrations), adolescents spent about ten hours per week in family-related activities. • After combining six categories of peer time (e.g., going to movies, going on dates, talking on phone), adolescents spent approximately 23 hours per week with peers – more than twice as much time as with family. The Relationships between Time Use Categories and Problem Behaviors • Time spent in housework and sibling care, and television watching had no main effect on any of the five problem behaviors. • Involvement in extracurricular activities and hobbies had a modest protective influence on sexual activity. • Time spent in paid work was related to heavy drinking for younger, but not for older, adolescents. While time spent on homework averaged only slightly more than an hour per day (or eight hours per week), it is associated with less cigarette smoking, less illicit drug use, and less delinquency. Home- work does not protect against heavy drinking but it does have a protective effect on sexual activity for younger adolescents. • Sports involvement was associated with less cigarette smoking and less illicit drug use. • Spending greater amounts of time with family protected adolescents from all five problem behaviors. • Spending greater amounts of time with peers was a risk factor for all five problem behaviors. The effect of time spent with peers had a much stronger influence on the substance use of white adolescents when compared to black adolescents. Also, the impact of time spent with peers had a stronger influence on male sexual activity when compared to female sexual activity. Study Specifics This study is based on data from 606 adolescents from west- ern New York state interviewed as part of a six-wave longitudinal study ...
Future Studies. The IMCI intervention is a strategy with 3 components: improve health providers’ skills, improve health systems to deliver IMCI, and improve family and community practices related to child health and development (WHO Regional Office for Eastern Mediterranean (EMRO), 2012). The objective of this study was limited in scope to improve health providers’ skills. Additional studies that continue to focus on this component might include:  A follow-up observation assessment of sick child consultations  Assessment of standard IMCI implementation and post-implementation quality of care  Assessment of health providers’ communication skills o Counseling offered to caretakers o Caretakers’ understanding of the child’s illness, how to provide home care and when to follow-up Further studies that focus on promoting healthy family and community practices in the region have significant potential to improve child survival. These practices include exclusive breastfeeding for infants up to six months, adequate micronutrients, good hygiene, complete immunization, use of bed nets and care-seeking habits (WHO EMRO, 2012). It is also possible that determining the proportion of children who are not of Cameroonian descent among the children evaluated in the Far North health clinics might allow for future funding for vaccination coverage of these children in the facilities.
Future Studies. This project started when a parent of a galactosemic child with severe tremor advertised for tremor neurologists to come learn about galactosemia, and hopefully start working on answers for classic galactosemia patients with movement disorders. Most reports of neurological features do not list subjective disability or other severity measures (ex: tremor amplitude). In the general population, kinetic tremors that negatively impact quality of life are often underreported and undertreated [16, 38], and both mild and severe tremor by clinical standards can significantly impact quality of life [39, 40]. There is a dearth of information on the galactosemia community’s attitudes about neurological complications. Anecdotal reports suggest that neurological complications of galactosemia range from mild to severe. The full range of severity is informative for research questions on causes of symptoms and prediction of outcome. Surveys can capture patient and family perspectives on symptom severity, disability, and quality of life. We know from our preliminary data that surveys are not designed to capture all cases of mild symptoms. However, they can help us understand the perceived need for interventions. What kind of treatment trials might best serve the community? Are there enough subjects to power a certain type of trial? Quality of life and preference information gathered from the patient community enables us to develop future studies around community goals. Survey data may upend research assumptions about patient and family experiences of symptoms. While survey data clearly miss crucial details captured in direct exams, long-distance surveys offer the advantage of being accessible to a much larger group of subjects, particularly people who cannot travel to PGC meetings. We gathered initial information on self-reported tremor and impact of tremor from the pilot study participants. We plan to use our pilot data to design a survey for all Xxxxxxxxx-Xxxx classic galactosemia study participants (currently 168 individuals) to begin to better understand which neurological complications, if any, present the greatest challenges to quality of life for children and adults with classic galactosemia. We will review questions already used in movement disorders research to best identify motor symptoms like dystonia in lay terms [41-43]. Based on our pilot data, identifying non- tremor symptoms may be more challenging than tremor. We will include questions about impact of motor...
Future Studies. The immediate work will be to synthesize and fully characterize the [Fe(13)2]PF6 and determine if the acetonitrile ligands are capable of displacing the sulfonates. Furthermore, attempts to ligate other π-acceptor ligands onto [Fe(13)2]PF6 can address if the sulfonates could be displaced to obtain the desired octahedral FeIII complexes. If successful, the octahedral FeIII complexes could be examined for their redox properties using cyclic voltmmatetry. Once the redox potential is established and shown to be feasible, a one-electron oxidation could xxxxxx access to the high valent FeIV center. Ideally, if the FeIV center is accessible, the complex will need to be isolated and fully characterized to determine if the sulfonates have converted the imines into amidos to stabilize the high valent FeIV center. If the FeIV center is not accessible or obtainable, different metal centers (potential alternative metal centers: MnII, CrII) could be used. The alternative metal centers mentioned are capable of accessing multiple oxidation states that would allow for studies to be done on the metal oxidation induced ring-chain isomerism. Chromium would be a particularly good metal for this study as multiple oxidations states, ranging from +2 to +6 (e.g. CrCl2 and Xxxxx Reagent), could be accessed. Once a complex with the cyclic form(s) of 13 is obtained, the next step would be to determine the rules for the metal-oxidation induced ring-chain isomerism. In this study, multiple ligands with different pendant nucleophiles are required. With the various pendant nucleophiles, oxidation studies could show how the pendant nucleophiles will respond to the change in metal oxidation states. In this respect, my work will help guide future designs of ERLs with potential applications in catalysis.
Future Studies. To pursue the reclamation proposal further, more detailed investigation and assessments should be carried out to firm up the development proposal and land use planning, covering aspects such as marine traffic, land traffic and transport, drainage, sewage, etc. Statutory EIA should be carried out to ascertain the environmental acceptability of the development proposal and to explore further mitigation / enhancement measures.
AutoNDA by SimpleDocs
Future Studies. The perspectives of perpetrators are not often included in studies of elder abuse. However, as our findings show, the relationship between victim and perpetrator is crucial in situations of abuse. For instance, the involvement of close family members in abuse had an influence on the choice of coping strategy of older persons. If we include research on perceptions and perspectives of perpetrators of elder abuse in future studies we will be better able to understand and explain the interaction between victim and perpetrator, as well as understanding victims’ help-seeking behaviors and coping strategies and perpetrators’ behavior, motives and reasons. There are a limited number of studies that focus on potential reporters, in particular older persons, of elder abuse. We know very little about factors that can influence reporting of elder abuse and motives of potential reporters. We have started this debate showing that non-abused older persons perceive abuse differently, and may therefore also detect and report abusive situations only in later, evident stages of abuse. Further increasing the knowledge about whether and how this reporting behavior is influenced and understanding of these factors will enable a xxxxxx mapping of reporting behavior of potential reporters, as well as their reasoning for reporting particular abusive situations or refraining from doing so. Moreover, help-seeking and reporting behavior of older victims of abuse is also understudied. We still do not fully understand why older victims refrain from reporting abuse. Although our study gave some indications (in that older victims help-seeking behavior depends on the type of abuse and the relationship with the perpetrator), more in-depth qualitative studies that include the perspective of perpetrators could shed light on this interaction. We do not know much about the possible combinations and relations between various types of abuse experienced, different perpetrators involved, and coping strategies used to deal with these situations. Studies are needed that can explain how one type of abuse, or a particular perpetrator can have an impact on the choice of reporting and coping strategy of older victims. Societal explanations of the occurrence of abuse by older participants can be a part of a rationale behind their reporting behavior and reasoning. As they see abuse as a social problem and society as responsible for abuse, their perceptions of the abusive situation and reporting of abuse wi...

Related to Future Studies

  • Re-Study If Re-Study of the Interconnection Facilities Study is required due to a higher queued project dropping out of the queue or a modification of a higher queued project pursuant to Section 4.4, Transmission Provider shall so notify Interconnection Customer in writing. Such Re-Study shall take no longer than sixty (60) Calendar Days from the date of notice. Any cost of Re-Study shall be borne by the Interconnection Customer being re-studied.

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Trials The Ship shall run the following test and trials:

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Commercialization Plan On a Product by Product basis, not later than sixty (60) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory, the MSC shall prepare and approve a rolling multiyear (not less than three (3) years) plan for Commercializing such Product in the Copromotion Territory (the "Copromotion Territory Commercialization Plan"), which plan includes a comprehensive market development, marketing, sales, supply and distribution strategy for such Product in the Copromotion Territory. The Copromotion Territory Commercialization Plan shall be updated by the MSC at least once each calendar year such that it addresses no less than the three (3) upcoming years. Not later than thirty (30) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory and thereafter on or before September 30 of each calendar year, the MSC shall prepare an annual commercialization plan and budget (the "Annual Commercialization Plan and Budget"), which plan is based on the then current Copromotion Territory Commercialization Plan and includes a comprehensive market development, marketing, sales, supply and distribution strategy, including an overall budget for anticipated marketing, promotion and sales efforts in the upcoming calendar year (the first such Annual Development Plan and Budget shall cover the remainder of the calendar year in which such Product is anticipated to be approved plus the first full calendar year thereafter). The Annual Commercialization Plan and Budget will specify which Target Markets and distribution channels each Party shall devote its respective Promotion efforts towards, the personnel and other resources to be devoted by each Party to such efforts, the number and positioning of Details to be performed by each Party, as well as market and sales forecasts and related operating expenses, for the Product in each country of the Copromotion Territory, and budgets for projected Pre-Marketing Expenses, Sales and Marketing Expenses and Post-Approval Research and Regulatory Expenses. In preparing and updating the Copromotion Territory Commercialization Plan and each Annual Commercialization Plan and Budget, the MSC will take into consideration factors such as market conditions, regulatory issues and competition.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

Time is Money Join Law Insider Premium to draft better contracts faster.